KKR tables 'best and final' $2.3 billion offer to buy UK's Assura

KKR has made a 'best and final' offer of 52.1 pence a share, including dividends, to acquire UK healthcare real estate investor Assura, valuing the company at approximately £1.7 billion ($2.29 billion). This proposal surpasses the previous offer of 51.7 pence from rival Primary Health Properties, as Assura becomes the latest UK company targeted for privatization by overseas private equity firms attracted by lower valuations.

Analysis

U.S. private equity firm KKR, in collaboration with Stonepeak Partners, has presented a 'best and final' offer of 52.1 pence per share, including dividends, to acquire UK healthcare real estate investor Assura. This offer values Assura at nearly £1.7 billion ($2.29 billion) and surpasses a rival bid of 51.7 pence per share from Primary Health Properties. This development highlights a continuing trend of overseas private equity firms acquiring UK-listed companies, driven by perceptions of cheap valuations in the UK market. The positive sentiment scores for both KKR (0.7) and Assura (0.6) indicate a favorable market reception to the proposed transaction for both entities. The 'best and final' status of KKR's offer suggests a strong likelihood of the deal proceeding, which would see Assura taken private, joining other UK companies recently acquired under similar circumstances. This specific M&A activity underscores private equity's interest in the stable, income-generating healthcare real estate sector.

Key Decisions for Investors

• Assura shareholders should note the 'best and final' nature of KKR's 52.1 pence offer, indicating limited potential for further bidding upside and providing a clear valuation benchmark for their holdings.
• Investors in KKR may view this acquisition as a strategic move to expand its real estate portfolio with UK healthcare assets at potentially attractive valuations, aligning with the positive sentiment signal.
• The transaction reinforces the theme of UK assets being targeted by private equity due to perceived undervaluation; investors might consider screening for other UK-listed companies in resilient sectors like healthcare or specialized real estate that could attract similar M&A interest.